Stockscreener 앱 받기
8.82
3.04%
0.26
시간 외 거래:
8.82
전일 마감가:
$8.56
열려 있는:
$8.41
하루 거래량:
17.76M
Relative Volume:
0.51
시가총액:
$9.07B
수익:
$113.29M
순이익/손실:
$-351.47M
주가수익비율:
-22.63
EPS:
-0.3898
순현금흐름:
$-309.19M
1주 성능:
+12.79%
1개월 성능:
+2.44%
6개월 성능:
+223.08%
1년 성능:
+219.57%
1일 변동 폭
$8.345
$8.87
1주일 범위
$8.022
$9.30
52주 변동 폭
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
명칭
Immunitybio Inc
전화
(844) 696-5235
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.82 | 8.80B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2025-05-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 개시 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | BTIG Research | Buy |
| 2023-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 개시 | Jefferies | Buy |
모두보기
Immunitybio Inc 주식(IBRX)의 최신 뉴스
After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News
Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st
ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey
ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks
5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat
Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat
IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits
Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha
ImmunityBio Stock To $6? - Trefis
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com
Will Anktiva Remain a Key Factor in ImmunityBio’s Revenue Expansion in 2026? - Bitget
ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral Capital - MarketBeat
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - TradingView
IBRX Stock Is Rising Pre-Market On This Cancer Treatment Expansion - Stocktwits
ImmunityBio gains on NCCN guidelines update (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treat - Bitget
Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA - Business Wire
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins - Stocktwits
ImmunityBio (NASDAQ:IBRX) Stock Price Down 2.1%Here's What Happened - MarketBeat
ImmunityBio rises after updates on cell therapy programs - MSN
IBRX Stock Jumps on Progress in NK Cell Therapy Production - Yahoo Finance
Is ImmunityBio, Inc. (IBRX) a good stock to buy now? - MSN
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: ImmunityBio’s Q4 2025 EPS beats forecast, stock surges - Investing.com Nigeria
ImmunityBio resubmits bladder cancer application to FDA By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN
BTIG Research Upgrades ImmunityBio (NASDAQ:IBRX) to "Strong-Buy" - MarketBeat
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells’ - Insider Monkey
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge - Yahoo Finance
ImmunityBio’s European Expansion Boosts Market Reach - timothysykes.com
ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.3%Time to Buy? - MarketBeat
IBRX Stock Rises 9%: ImmunityBio Reports Breakthrough In NK Cell Therapy Production - Stocktwits
ImmunityBio’s Market Expansion Amidst Financial Challenges - StocksToTrade
IBRX Stock: Anktiva Receives Approvals and Future Steps Ahead - Bitget
ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus - TechStock²
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking - Yahoo Finance
ImmunityBio Valuation: Paying 33x Sales for Anktiva - TradingView
IBRX Stock: Anktiva's Approvals and What Comes Next - Yahoo Finance
ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum - timothysykes.com
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - sharewise.com
ImmunityBio (NASDAQ:IBRX) Shares Gap UpWhat's Next? - MarketBeat
ImmunityBio Shares Surge 295% Year-to-Date: Should You Buy, Hold, or Sell? - Bitget
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 - PharmiWeb.com
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Investing News Network
Immunitybio Inc (IBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):